Abstract
CD47 is a tumor marker that inhibits phagocytosis thereby providing tumor cells with a means of escape from immune surveillance and elimination. Anti-CD47 therapy is a promising new immunotherapy across numerous tumor types but have not been tested in thymic epithelial tumors (TETs; thymomas and thymic carcinomas). TETs are rare tumors which are difficult to treat, especially with PD-1/PD-L1 checkpoint inhibitors, due to the excessive rates of immune-related adverse effects. This study investigated the levels of CD47 expression in TETs to explore the possibility of anti-CD47 therapies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
